| Vol. 6.07 – 1 March, 2021 |
| |
|
|
| Researchers investigated the role of the lncRNA CARMN, independent from miR-143 and miR-145, as a potential regulator of vascular smooth muscle cell phenotypes in vitro and the consequences of its loss during the development of atherosclerosis in vivo. [Circulation Research] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| High glucose induced cardiomyocyte hypertrophy, accompanied by abnormal mitochondrial morphology and function, and increased Orai1-mediated Ca2+ influx. [Cell Death & Disease] |
|
|
|
| Researchers developed a simple method that could drive cultured human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) toward maturity across a number of phenotypes, with the aim of utilizing mature hiPSC-CMs to model human cardiovascular disease. [Stem Cell Reports] |
|
|
|
| In vitro analyses showed that choline ameliorated calcium overload, downregulated STIM1, Orai1, and TRPC6, and inhibited thapsigargin-induced store-operated Ca2+ entry and 1-oleoyl-2-acetyl-sn-glycerol-induced receptor-operated Ca2+ entry in angiotensin II-treated cardiomyocytes. [Laboratory Investigation] |
|
|
|
| Cardiac myofibroblasts were transduced with Channelrhodopsin-2, which allowed acute and selective increase of myofibroblast current, and plated on top of cardiomyocytes. [Scientific Reports] |
| |
|
|
| The authors demonstrated that oscillating delta-like 1 produced by myogenic cells is an indispensable Notch ligand for self-renewal of muscle stem cells in mice. [Nature Communications] |
|
|
|
| Researchers report that, with age, Mind bomb-1 (Mib1) plays an important role in skeletal muscle maintenance via proteasomal degradation-dependent regulation of α-actinin 3 (Actn3). [Nature Communications] |
|
|
|
| Scientists identified a novel lncRNA, Mir22hg, that was significantly up-regulated during myoblast differentiation and was highly expressed in skeletal muscle. They validated that Mir22hg promoted the myoblasts differentiation, in vitro. [Molecular Therapy-Nucleic Acids] |
|
|
|
| Researchers report that in murine myoblasts chicken ovalbumin upstream promoter-factor II (COUP-TFII) interacted with thyroid nuclear receptor alpha (THRA) and modulated THRA binding to thyroid response elements. [Scientific Reports] |
| |
|
|
| Investigators demonstrated that Forkhead Box F1 (FOXF1) transcription factor was uniquely expressed in fusion positive rhabdomyosarcoma (FP-RMS) and was required for FP-RMS tumorigenesis. The PAX3-FOXO1 directly bound to FOXF1 enhancers and induced FOXF1 gene expression. [Oncogene] |
|
|
|
| While genomic deletion of BRD4-associated enhancer in smooth muscle cells in vitro decreased CCAAT enhancer binding protein delta (Cebpd) transcripts, BRD4 gene silencing also diminished Cebpd mRNA and protein, indicative of a BRD4 control over CEBPD expression. [Molecular Therapy-Methods & Clinical Development] |
|
|
|
|
| In adaptive immunity, effector T cells, especially Th17 cells, lead to the pathogenesis of cardiac fibrosis, including the distal fibrosis and scar formation. Cardiomyocytes protectors, Treg cells, inhibit reduce the inflammatory response, then directly trigger the regeneration of local progenitor cell via IL-10. [Signal Transduction and Targeted Therapy] |
|
|
|
|
| Sarepta Therapeutics, Inc. announced that the FDA has approved AMONDYS 45. AMONDYS 45 is an antisense oligonucleotide from Sarepta’s phosphorodiamidate morpholino oligomer platform, indicated for the treatment of DMD in patients with a confirmed mutation amenable to exon 45 skipping. [Sarepta Therapeutics, Inc.] |
|
|
|
| SHEPHERD Therapeutics announced a collaboration with the Mayo Clinic to advance research in rhabdomyosarcoma, a rare pediatric cancer with few treatment options. [SHEPHERD Therapeutics (Cision US Inc.)] |
|
|
|
|
| June 21 – 26, 2021 Virtual |
|
|
|
|
|
| Karolinska Institutet – Stockholm, Sweden |
|
|
|
| Aix-Marseille University – Marseille, France |
|
|
|
| University of Alabama at Birmingham – Birmingham, Alabama, United States |
|
|
|
| Baylor College of Medicine – Houston, Texas, United States |
|
|
|
| The University of Utah School of Medicine – Salt Lake City, Utah, United States |
|
|
|
|